This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Post #27 describes the usual case. This is about the unusual one.
Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything that follows.
Adding the measurement that post #31 says would settle it.
One caution on orforglipron phase 2: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
The version of orforglipron phase 2 that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
On post #31 — agreed on the reasoning, with one qualification.
People arriving without having read it should be welcome and should say so, because a question from someone who has not read it frequently exposes an assumption everyone else made.
Posting it because the silence on this was starting to look like agreement.
What I want from this orforglipron phase 2 thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it.
Orforglipron phase 2 is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
Careful with the language on orforglipron phase 2. "Not detected" and "not present" are different findings and the first is a statement about the method.
Nothing to add, except that this is the answer I would give if asked.
This follows post #40 rather than contradicting it.
Adding what did not work for me on orforglipron phase 2, since the failures never get written up and they are half the useful information.
Worth separating two things that post #43 runs together.
The claim about orforglipron phase 2 upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later.
Speaking for myself and not for anyone else who has posted here.
Practical experience of orforglipron phase 2, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.
Recording who prepared each section makes the summary attributable, which matters when somebody reads it eighteen months later and wants to ask a question.
I had written a reply contradicting post #46 and deleted it. Here is what survived.
Filing a mild objection to the consensus on orforglipron phase 2. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.
Answering the question post #50 raises rather than the one it answers.
One more thing on orforglipron phase 2 that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.
What I can speak to on orforglipron phase 2 is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
Following this. I have the same question and no better information than the first post.
Adding a reference point for orforglipron phase 2. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to.
I would rather say I do not know than round it up to an answer.
Post #53 put the caveat in the right place and I want to underline it.
Orforglipron phase 2 is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
Building on post #57 rather than restating it.
Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question? (3) Was the population sufficiently similar to your population to apply the results? (4) What was the absolute effect, not just the relative one? (5) What are the two strongest criticisms available?
That reframing is the whole thing. The facts I already had.